The challenges faced by oncologists in using biomarker-based tests were underlined in a recent article by Dr. Marcus Neubauer in OncLive. In recent posts in this blog I have focused on the challenges of interpreting genomic data, but Dr. Neubauer emphasizes two...
Interesting survey (sponsored by Boehringer Ingelheim) of pulmonologists and pathologists regarding barriers to adoption of biomarker testing of lung cancer patients. Key finding: “Both pulmonologists and pathologists said the biggest challenges with biomarker...
Further motivation to drive the advancement of molecular diagnostics ever more vigorously. Diagnostic Errors Are the Most Common Type of Medical Mistake | TIME.com.
Mathematical models out-perform doctors in predicting cancer patients responses to treatment. Key statement: “For all three predictions and at both time points, the mathematical models substantially outperformed the doctors’ predictions, with the...
We have just conducted a review of the biomarkers in drug labels to complete the population of the theranostic clinical biomarkers in BiomarkerBase™, and it was not surprising to note how well-represented the cytochrome p450’s are in the labels of approved...